Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Other Announcement

Novelix Pharmaceuticals informs shareholders that the Annual Report for FY 2025-26 and the 32nd AGM notice are available on the Company's website.

Novelix Pharmaceuticals Annual Report

Novelix Pharmaceuticals filed its Annual Report and AGM Notice for the financial year 2025-26. The 32nd Annual General Meeting is scheduled for September 30, 2026.

Novelix Pharmaceuticals Annual General Meeting

Novelix Pharmaceuticals Limited will hold its 32nd Annual General Meeting on September 30, 2026. The company has fixed September 23, 2026, as the cut-off date for e-voting.

Novelix Pharmaceuticals Management Change

Novelix Pharmaceuticals Limited appointed Mr. Gnana Prakash Gattu as Whole-time Director for a five-year term. The appointment, effective August 29, 2026, awaits shareholder approval.

Execution

5 years

Novelix Pharmaceuticals Board Meeting Outcome

Novelix Pharmaceuticals Ltd approved the AGM notice and appointed Mr. Gnana Prakash Gattu as a Whole-time Director in its board meeting outcome.

Novelix Pharmaceuticals Board Meeting Date

Novelix Pharmaceuticals Limited will hold a board meeting on August 29, 2026, to discuss the AGM notice, annual report, and a director appointment.

Novelix Pharmaceuticals Capacity Expansion: ₹0.03 Cr Investment

Novelix Pharmaceuticals executed a five-year land lease for micro algae cultivation in Telangana. The company will pay a monthly rent of Rs. 5,000 for 0.925 acres.

Value

₹0.03 Cr

Execution

5 years

Novelix Pharmaceuticals Other Announcement

Novelix Pharmaceuticals filed its Statement of Deviation and Variation for the quarter ended June 30, 2026, reporting no deviations in fund utilization.

Novelix Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.2 Cr, Up 1100.0% YoY

Novelix Pharmaceuticals Ltd reported revenue from operations of ₹36.9 Cr (+64.7% YoY) and net profit of ₹1.2 Cr (+1100.0% YoY) for Q1 FY27.

Key figure

Net profit ₹1.2 Cr · +1100.0% YoY

Novelix Pharmaceuticals Board Meeting Date

Novelix Pharmaceuticals has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026.

Novelix Pharmaceuticals Promoter Buying: ₹13.95 Cr

Novelix Pharmaceuticals promoters acquired 3,37,500 shares worth Rs. 6.75 Crore via warrant conversion. The acquisition increases the promoter group's consolidated equity stake in the company.

Value

₹13.95 Cr

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharmaceuticals allotted 25,00,000 equity shares to promoter group entities following warrant conversion. This increased the promoter group stake from 36.42% to 39.35%.

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharma approved a total equity raise of ₹74.34 Crore through a promoter warrant conversion and a non‑promoter preferential issue. The issue adds 4.5 million shares to its paid‑up capital.

Value

₹74.34 Cr

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharmaceuticals allotted 45,75,000 equity shares, raising approximately Rs. 11.90 Crore. This includes warrant conversions for promoters and a preferential issue to 16 non-promoter investors.

Value

₹11.90 Cr